Storys zum Thema Pharmaindustrie

SHL Medical

SHL Medical achieves EcoVadis® Silver Medal and sets ambitious science-based climate targets

Biomay AG

Biomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services

Gerresheimer AG

Gerresheimer awarded EcoVadis Gold status again

Duesseldorf (ots) - - Gerresheimer among the top 5% of assessed businesses - Total score increases to 72/100 points - Status demonstrates consistent implementation of CSR strategy Gerresheimer, an innovative provider of systems and solutions and a global partner for the pharma, biotech, and cosmetic industries, has once again been awarded Gold status by the ratings agency EcoVadis. EcoVadis assesses the performance of ...

SHL Medical

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...

Aurubis AG

2

Press Release: Aurubis subsidiary RETORTE expanding selenium production for profitable growth markets

eleva GmbH

Björn Cochlovius New CEO of Eleva / Seasoned Molecular Biologist and Entrepreneur Leads German Biotech Company into its Next Development

Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...

Adragos Pharma

Successful transaction: Adragos Pharma has officially taken over Clinigen’s development unit, Lamda Laboratories near Athens, Greece

Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...

Adragos Pharma

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories

Munich / London / Athens (ots) - - Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment - Agreement includes further product development activities for Clinigen Limited - Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally Munich-based pharmaceutical contract ...

Adragos Pharma

Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan

Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...

Fördergesellschaft IZB mbH

Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris

Technische Universität München

Nanoswitches for tumor targeting

TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de Video: https://www.youtube.com/watch?v=_xXV0mCke1g NEWS RELEASE Nanoswitches for tumor targeting TUM spin-off Plectonic develops antibody-based immunotherapies Plectonic Biotech, a spin-off of the Technical University of Munich (TUM), has developed a nanoswitch that binds immune cells to tumor cells. The goal is to facilitate the development of ...

RHEACELL GmbH und Co. KG

Stem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research

Adragos Pharma

Adragos Pharma to acquire Sanofi's manufacturing site in Kawagoe, Japan

benfovir AG

benfovir AG has reached another milestone by completing the first part of the Phase 1 trial testing transketolase inhibitor / benfo-oxythiamine (B-OT)

Darmstadt (ots) - benfovir AG, a German pharmaceutical company focused on developing small molecules against viral infections such as SARS-CoV-2, dengue and herpes virus, today announced that the first part of the Phase 1 clinical trial (BV-01-101/ EudraCT Number: 2021-005616-60.) designed to evaluate the safety, ...

LEUKOCARE AG

Leukocare announces new management structure to support global set-up and accelerate growth

Martinsried/Munich (ots) - Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, today announced the introduction of a new management structure, effective July 1st, 2022, designed to support the global organizational set-up and to further accelerate the company’s growth. The newly established Executive Board ...

benfovir AG

benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT/ B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS

Darmstadt (ots) - benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers. benfovir AG, a German pharmaceutical biotechnology company focused on developing small molecules against viral infection such as ...

Technische Universität München

Multi-functional bandage helps wounds to heal

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808- email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37410 Pictures: https://mediatum.ub.tum.de/1659268 NEWS RELEASE Biomolecular film adheres to sensitive tissue and releases active ingredients Multi-functional bandage helps wounds to heal Researchers at the ...

Hypertrust Patient Data Care

HPDC Launches the World’s First All-in-One Supply Chain Management Solution for Advanced & Personalized Therapies

Munich/Nice (ots) - Hypertrust Patient Data Care (HPDC) today announced the global launch of its extended Hypertrust X-Chain supply chain management solution for Advanced & Personalized Therapies (APT). It is the worldwide first solution that allows biotech and pharmaceutical companies to design, set up, plan, ...

News Direct

Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass

BOSTON, MA (ots) - --News Direct-- Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose ...

Sysmex Inostics GmbH

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...

Technische Universität München

mRNA containing nanoparticles in the light of neutrons - investigations at FRM II aid in the development of mRNA medications

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37120 High resolution images: https://mediatum.ub.tum.de/1638436 NEWS RELEASE Optimization of mRNA ...

Brenntag SE

Brenntag’s Pharma section signs exclusive agreement for health-promoting product line Akovita ELIP in EMEA